e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Diagnosis and prognosis in thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic value of metabolic imaging in non small cell lung cancers with neoplasic pleural effusion
B. Duysinx, J. L. Corhay, D. Nguyen, T. Bury, R. Hustinx, R. Louis (Liege, Belgium)
Source:
Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Session:
Diagnosis and prognosis in thoracic oncology
Session type:
Oral Presentation
Number:
1281
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Duysinx, J. L. Corhay, D. Nguyen, T. Bury, R. Hustinx, R. Louis (Liege, Belgium). Prognostic value of metabolic imaging in non small cell lung cancers with neoplasic pleural effusion. Eur Respir J 2007; 30: Suppl. 51, 1281
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Challenges in the management of SCLC
Related content which might interest you:
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM)
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Diagnostic significance of ADAM8 in non-small cell lung cancer and malignant pleural effusion
Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology
Year: 2008
Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer
Source: Annual Congress 2005 - What's new in the pleura
Year: 2005
Evaluation of concomitant pleural effusions in patients with lung cancers
Source: Eur Respir J 2007; 30: Suppl. 51, 668s
Year: 2007
Biological characteristics of dendritic cells from malignant pleural effusions in patients with lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006
Malignant pleural effusion cells show aberrant glucose metabolism gene expression
Source: Eur Respir J 2011; 37: 1453-1465
Year: 2011
Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
Prognostic factors in diffuse malignant pleural mesothelioma
Source: Eur Respir J 2007; 30: Suppl. 51, 755s
Year: 2007
Prognostic factors in diffuse malignant pleural mesothelioma
Source: Eur Respir J 2003; 22: Suppl. 45, 62s
Year: 2003
Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung?
Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice?
Year: 2019
Prognostic significance of neutrophil predominance in pleural fluid in patients with malignant effusion
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion
Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions
Year: 2013
An update on treatment of malignant pleural effusion with or without known primary bronchial adenocarcinoma
Source: Annual Congress 2006 - Medical and surgical management of malignant pleuritis
Year: 2006
Oncodrivers in malignant pleural effusions associated with non-small cell lung cancer
Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema
Year: 2020
Biochemical and cytological features of metastatic pleural effusions in breast cancer
Source: Eur Respir J 2007; 30: Suppl. 51, 671s
Year: 2007
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
The role of diagnostic thoracoscopy in patients with lung cancer and pleural effusion
Source: Eur Respir J 2003; 22: Suppl. 45, 542s
Year: 2003
Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma
Source: Eur Respir J 2006; 28: Suppl. 50, 784s
Year: 2006
Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients
Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept